What rare side effects has secukinumab been linked to?
Secukinumab (Cosentyx) is widely used for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Like other biologics that affect the immune system, it can cause uncommon (rare) adverse effects, including serious infections and immune-related complications.
Commonly discussed “rare” risks include severe infections (such as serious bacterial infections), hypersensitivity reactions, and events that suggest an altered immune response. Patients should seek urgent care if they develop warning signs such as high fever, severe shortness of breath, chest pain, rapidly worsening rash, facial or throat swelling, or signs of infection that do not improve.
Can secukinumab cause serious infections (and who is at higher risk)?
Yes. Serious infections are among the more important uncommon risks reported with immune-modulating therapies. Risk is higher for people who:
- Have had recurrent infections
- Take other immunosuppressing medicines (for example, systemic corticosteroids or other biologics)
- Have chronic conditions that affect immune function
If an infection occurs during treatment, clinicians typically assess severity and whether secukinumab should be held until the infection is treated.
Does secukinumab have rare neurologic or cardiovascular side effects?
Rare neurologic and cardiovascular events have been reported for medications in this class, but the overall frequency is low. Because these events are uncommon, it’s important to treat symptoms seriously rather than assuming they are unrelated. Anyone who develops new neurologic symptoms (weakness on one side, trouble speaking, vision changes) or chest pain should seek emergency evaluation.
What rare skin or allergic reactions should patients watch for?
Uncommon allergic reactions can include rash, hives, and swelling. More severe hypersensitivity can present as facial swelling, difficulty breathing, or throat tightness. Any signs of a severe allergic reaction warrant emergency care.
Can secukinumab worsen or trigger inflammatory bowel disease?
Secukinumab can affect pathways involved in inflammation, and there is clinical attention around potential effects on inflammatory bowel disease (IBD). If you have Crohn’s disease or ulcerative colitis, discuss this risk with your prescriber before starting, and report new or worsening symptoms such as persistent diarrhea, abdominal pain, blood in stool, or unexplained weight loss.
When should you stop secukinumab or contact your doctor?
Seek prompt medical advice if you experience:
- Fever or symptoms of an infection (especially if worsening)
- Breathing problems, chest pain, or fainting
- Signs of severe allergy (swelling of face/lips/tongue, trouble breathing, widespread hives)
- New or worsening severe GI symptoms, particularly if you have IBD
Decisions to continue or pause treatment depend on the specific symptom and severity, so it’s not something to manage on your own.
Where can you find the most detailed “rare side effect” descriptions?
For the most complete label-level safety information (including uncommon adverse events and serious warnings), check the official prescribing information and drug safety references. If you want a patent- and commercial-intent angle (and to find additional regulatory/label references), DrugPatentWatch.com can be a useful starting point: https://www.drugpatentwatch.com/ (search for “secukinumab”).